Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1978 1
1988 1
1989 1
1996 2
1997 1
1998 1
1999 1
2000 1
2001 2
2002 1
2003 1
2005 2
2006 5
2007 3
2008 3
2009 4
2010 6
2011 6
2012 4
2013 3
2014 4
2015 4
2016 1
2017 2
2018 1
2019 1
2020 1
2021 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

64 results

Results by year

Filters applied: . Clear all
Page 1
Recent development of anticancer therapeutics targeting Akt.
Morrow JK, Du-Cuny L, Chen L, Meuillet EJ, Mash EA, Powis G, Zhang S. Morrow JK, et al. Among authors: mash ea. Recent Pat Anticancer Drug Discov. 2011 Jan;6(1):146-59. doi: 10.2174/157489211793980079. Recent Pat Anticancer Drug Discov. 2011. PMID: 21110830 Free PMC article. Review.
Cell-specific targeting by heterobivalent ligands.
Josan JS, Handl HL, Sankaranarayanan R, Xu L, Lynch RM, Vagner J, Mash EA, Hruby VJ, Gillies RJ. Josan JS, et al. Among authors: mash ea. Bioconjug Chem. 2011 Jul 20;22(7):1270-8. doi: 10.1021/bc1004284. Epub 2011 Jun 16. Bioconjug Chem. 2011. PMID: 21639139 Free PMC article.
Enhanced targeting with heterobivalent ligands.
Xu L, Vagner J, Josan J, Lynch RM, Morse DL, Baggett B, Han H, Mash EA, Hruby VJ, Gillies RJ. Xu L, et al. Among authors: mash ea. Mol Cancer Ther. 2009 Aug;8(8):2356-65. doi: 10.1158/1535-7163.MCT-08-1183. Epub 2009 Aug 11. Mol Cancer Ther. 2009. PMID: 19671749 Free PMC article.
Magnetic resonance imaging of RRx-001 pharmacodynamics in preclinical tumors.
Raghunand N, Scicinski J, Guntle GP, Jagadish B, Mash EA, Bruckheimer E, Oronsky B, Korn RL. Raghunand N, et al. Among authors: mash ea. Oncotarget. 2017 Jun 12;8(60):102511-102520. doi: 10.18632/oncotarget.18455. eCollection 2017 Nov 24. Oncotarget. 2017. PMID: 29254266 Free PMC article.
Heterobivalent ligands target cell-surface receptor combinations in vivo.
Xu L, Josan JS, Vagner J, Caplan MR, Hruby VJ, Mash EA, Lynch RM, Morse DL, Gillies RJ. Xu L, et al. Among authors: mash ea. Proc Natl Acad Sci U S A. 2012 Dec 26;109(52):21295-300. doi: 10.1073/pnas.1211762109. Epub 2012 Dec 10. Proc Natl Acad Sci U S A. 2012. PMID: 23236171 Free PMC article.
Synthesis of 13C and 15N labeled 2,4-dinitroanisole.
Jagadish B, Field JA, Chorover J, Sierra-Alvarez R, Abrell L, Mash EA. Jagadish B, et al. Among authors: mash ea. J Labelled Comp Radiopharm. 2014 May 30;57(6):434-6. doi: 10.1002/jlcr.3192. Epub 2014 Mar 5. J Labelled Comp Radiopharm. 2014. PMID: 24596018
Linear scaffolds for multivalent targeting of melanocortin receptors.
Dehigaspitiya DC, Anglin BL, Smith KR, Weber CS, Lynch RM, Mash EA. Dehigaspitiya DC, et al. Among authors: mash ea. Org Biomol Chem. 2015 Dec 21;13(47):11507-17. doi: 10.1039/c5ob01779c. Epub 2015 Oct 13. Org Biomol Chem. 2015. PMID: 26461460
64 results